Medtronic drops as MiniMed IPO dilution and $157M charge weigh on FY26 outlook
Medtronic shares are sliding as investors continue to reprice the stock after the company cut its FY2026 non-GAAP EPS outlook to $5.50–$5.54 from $5.62–$5.66. The cut was tied to MiniMed’s IPO-related dilution and a $157 million one-time charge connected to future payments owed to Blackstone.
1) What’s moving the stock
Medtronic (MDT) is down about 3% as the market continues to digest a reduced fiscal 2026 profit outlook tied to its diabetes unit MiniMed. The company disclosed that MiniMed is expected to recognize a one-time $157 million charge in Q4 FY2026 related to future payments owed to Blackstone, and that the MiniMed IPO structure adds incremental Q4 dilution to Medtronic’s consolidated results. (sec.gov)
2) The key numbers investors are reacting to
Medtronic now expects FY2026 non-GAAP EPS of $5.50 to $5.54, down from its prior range of $5.62 to $5.66. The company also quantified the Q4 impacts: roughly a $0.08 per share hit from the one-time charge (based on its ~90% ownership interest) and about $0.04 per share of dilution in Q4 tied to the MiniMed IPO. (sec.gov)
3) Why it matters right now
With the fiscal year ending April 24, 2026, investors are focusing on near-term earnings power and the risk that one-off items in Q4 can reset valuation expectations for a large-cap medtech name. The MiniMed transaction was intended to sharpen the portfolio, but the immediate accounting and IPO-related dilution have become a headline drag on FY2026 EPS. (sec.gov)
4) What to watch next
Next catalysts are Medtronic’s Q4 FY2026 results and any updated cadence for how MiniMed-related dilution and payments flow through FY2027 expectations. Investors will also be watching whether Medtronic offsets the Q4 headwinds with stronger segment execution (especially in cardiac and surgical portfolios) or cost actions that stabilize margins into the next fiscal year. (sec.gov)